Mohammad Houshmand, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2022 | 686 | 1.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1331 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 1348 | 0.370 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 2410 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5662 | 0.270 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2017 | 1643 | 0.260 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1895 | 0.260 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 3609 | 0.200 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2022 | 430 | 0.170 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 173 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 6123 | 0.170 |
Why?
|
| Cell Cycle | 2 | 2018 | 2926 | 0.160 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2018 | 176 | 0.150 |
Why?
|
| Cytarabine | 1 | 2018 | 697 | 0.140 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 1007 | 0.130 |
Why?
|
| Biomimetics | 1 | 2017 | 171 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 646 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2022 | 5300 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13630 | 0.110 |
Why?
|
| Coculture Techniques | 1 | 2017 | 1334 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2018 | 10421 | 0.100 |
Why?
|
| Autophagy | 1 | 2018 | 1326 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2021 | 2010 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 3700 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2017 | 932 | 0.090 |
Why?
|
| Pyridines | 1 | 2021 | 2872 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 3409 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2813 | 0.070 |
Why?
|
| Apoptosis | 2 | 2021 | 9478 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2021 | 11505 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8529 | 0.050 |
Why?
|
| Microsomes, Liver | 1 | 2021 | 172 | 0.050 |
Why?
|
| Half-Life | 1 | 2021 | 649 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2018 | 317 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2018 | 359 | 0.040 |
Why?
|
| G1 Phase | 1 | 2018 | 403 | 0.040 |
Why?
|
| Chloroquine | 1 | 2018 | 274 | 0.040 |
Why?
|
| Humans | 6 | 2022 | 761098 | 0.030 |
Why?
|
| Drug Design | 1 | 2021 | 1045 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 3060 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 16947 | 0.030 |
Why?
|
| Adenine | 1 | 2018 | 986 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 5993 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 6198 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 2915 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 168083 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 8164 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2018 | 4111 | 0.020 |
Why?
|
| Rats | 1 | 2021 | 23713 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2018 | 3758 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 81324 | 0.010 |
Why?
|
| Male | 1 | 2021 | 360675 | 0.000 |
Why?
|
| Female | 1 | 2021 | 392458 | 0.000 |
Why?
|